CD33 and diffuse large B-cell lymphoma: More recently, a study in B-NHL patients including CLL, DLBCL, marginal zone lymphoma (MZL), high‐grade B‐cell lymphoma (HGBL), mantle‐cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) and follicular lymphoma (FL) patients was carried out to investigate the impact of MDSC number and subsets (CD14+CD33+HLA‐DR−/low for M‐MDSC, CD10‐HLA‐DR−/low for G‐MDSC) on B-NHL patient’s prognosis.